Wall Street analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce sales of $114.14 million for the current fiscal quarter, according to Zacks Investment Research. Five analysts have issued estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $71.40 million and the highest is $134.47 million. Nektar Therapeutics posted sales of $36.34 million in the same quarter last year, which suggests a positive year-over-year growth rate of 214.1%. The business is scheduled to report its next earnings report on Thursday, November 2nd.

According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $114.14 million for the current financial year, with estimates ranging from $219.00 million to $314.20 million. For the next year, analysts forecast that the company will report sales of $199.03 million per share, with estimates ranging from $152.89 million to $282.15 million. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that that provide coverage for Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last posted its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.04). The firm had revenue of $34.60 million during the quarter, compared to the consensus estimate of $33.64 million. Nektar Therapeutics had a negative net margin of 157.14% and a negative return on equity of 1,223.34%. Nektar Therapeutics’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.36) earnings per share.

NKTR has been the subject of several research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 price target on shares of Nektar Therapeutics in a research note on Friday, July 21st. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research note on Tuesday, August 1st. ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research note on Monday, June 26th. Finally, BidaskClub lowered Nektar Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 4th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $26.10.

COPYRIGHT VIOLATION WARNING: “$114.14 Million in Sales Expected for Nektar Therapeutics (NKTR) This Quarter” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/20/114-14-million-in-sales-expected-for-nektar-therapeutics-nktr-this-quarter-2.html.

In other Nektar Therapeutics news, SVP Ivan P. Gergel sold 54,920 shares of the company’s stock in a transaction that occurred on Tuesday, July 18th. The stock was sold at an average price of $21.10, for a total transaction of $1,158,812.00. Following the completion of the transaction, the senior vice president now owns 98,492 shares of the company’s stock, valued at approximately $2,078,181.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $21.54, for a total value of $1,794,992.82. Following the transaction, the chief executive officer now directly owns 235,837 shares of the company’s stock, valued at approximately $5,079,928.98. The disclosure for this sale can be found here. Insiders have sold a total of 320,962 shares of company stock valued at $6,615,210 in the last ninety days. 5.44% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Louisiana State Employees Retirement System raised its position in Nektar Therapeutics by 0.8% during the 2nd quarter. Louisiana State Employees Retirement System now owns 63,200 shares of the biopharmaceutical company’s stock valued at $1,236,000 after purchasing an additional 500 shares during the last quarter. LS Investment Advisors LLC raised its position in Nektar Therapeutics by 8.8% during the 2nd quarter. LS Investment Advisors LLC now owns 6,594 shares of the biopharmaceutical company’s stock valued at $129,000 after purchasing an additional 535 shares during the last quarter. World Asset Management Inc raised its position in Nektar Therapeutics by 5.6% during the 2nd quarter. World Asset Management Inc now owns 10,167 shares of the biopharmaceutical company’s stock valued at $199,000 after purchasing an additional 539 shares during the last quarter. Municipal Employees Retirement System of Michigan raised its position in Nektar Therapeutics by 1.7% during the 1st quarter. Municipal Employees Retirement System of Michigan now owns 34,920 shares of the biopharmaceutical company’s stock valued at $820,000 after purchasing an additional 570 shares during the last quarter. Finally, Meadow Creek Investment Management LLC raised its position in Nektar Therapeutics by 11.1% during the 1st quarter. Meadow Creek Investment Management LLC now owns 6,160 shares of the biopharmaceutical company’s stock valued at $145,000 after purchasing an additional 616 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics (NASDAQ:NKTR) opened at 21.75 on Wednesday. The company’s market capitalization is $3.40 billion. Nektar Therapeutics has a 52-week low of $11.41 and a 52-week high of $24.88. The firm has a 50-day moving average price of $20.15 and a 200 day moving average price of $19.77.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.